Asahi Ka­sei ac­quires Biono­va and its shiny new Cal­i­for­nia site

Just months af­ter it opened a new GMP man­u­fac­tur­ing site, the US-based bio­phar­ma CD­MO Biono­va Sci­en­tif­ic has been ac­quired by Asahi Ka­sei Med­ical.

The com­pa­ny an­nounced the ac­qui­si­tion Mon­day evening, how­ev­er, the deal was fi­nal­ized April 14, the com­pa­ny said.

Biono­va spe­cial­izes in com­plex next-gen­er­a­tion an­ti­body drugs, which can be dif­fi­cult to man­u­fac­ture. It launched the full-ser­vice com­mer­cial-ready GMP man­u­fac­tur­ing site in Fre­mont, CA, just north of San Jose, in Oc­to­ber. With the ac­qui­si­tion, Asahi Ka­sei will get near­ly 80,000-square-feet of CD­MO fa­cil­i­ties and a num­ber of state-of-the-art in­stru­ments and equip­ment, in­clud­ing sin­gle-use biore­ac­tors. The ac­qui­si­tion will al­so al­low Asahi Ka­sei to add a CD­MO to its bio­process busi­ness.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN